Deferasirox

CHEMBL550348 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
373.4 g/mol
LogP
3.8
Phase
4

An oral iron chelator that binds excess iron in the body and promotes its excretion in the feces, used to treat chronic iron overload from blood transfusions in conditions like thalassemia and sickle cell disease. It is taken once daily as a dispersible tablet or film-coated tablet.

Молекулярная масса

373,4000 g/mol

LogP

3,80

TPSA

108,00 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Механизм действия

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1

InChI

InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)

Molecular Formula

C21H15N3O4

HBD / HBA

3 / 6

Вращаемые Связи

4

Тяжёлые Атомы

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

An oral iron chelator that binds excess iron in the body and promotes its excretion in the feces, used to treat chronic iron overload from blood transfusions in conditions like thalassemia and sickle cell disease. It is taken once daily as a dispersible tablet or film-coated tablet.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Deferasirox is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL550348. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 214348. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.